The Current Ratio as of November 2024 (TTM) for Entrada Therapeutics, Inc. (TRDA) is 5.70

According to Entrada Therapeutics, Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 5.70. This represents a change of 79.26% compared to the average of 3.18 of the last 4 quarters.

Entrada Therapeutics, Inc. (TRDA) Historical Current Ratio (quarterly & annually)

How has TRDA Current Ratio performed in the past?

The mean historical Current Ratio of Entrada Therapeutics, Inc. over the last ten years is 15.46. The current 5.70 Current Ratio has changed 3.59% with respect to the historical average. Over the past ten years (40 quarters), TRDA's Current Ratio was at its highest in in the December 2021 quarter at 44.46. The Current Ratio was at its lowest in in the March 2020 quarter at 0.

Entrada Therapeutics, Inc. (TRDA) Current Ratio by Quarter and Year

Discovering the peaks and valleys of Entrada Therapeutics, Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Entrada Therapeutics, Inc. (TRDA) Average Current Ratio

How has TRDA Current Ratio performed in the past?

The current Current Ratio of Entrada Therapeutics, Inc. (TRDA) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

Entrada Therapeutics, Inc. (TRDA) Current Ratio vs. Peers

How is TRDA’s Current Ratio compared to its peers?

Entrada Therapeutics, Inc.’s Current Ratio is less than Molecular Partners AG (14.58), less than PMV Pharmaceuticals, Inc. (19.22), less than Monte Rosa Therapeutics, Inc. (6.56), less than Vigil Neuroscience, Inc. (8.39), less than Third Harmonic Bio, Inc. (41.13), less than Cullinan Oncology, Inc. (28.87), less than Edgewise Therapeutics, Inc. (30.24), less than Rallybio Corporation (7.52), less than Crinetics Pharmaceuticals, Inc. (16.09), less than Centessa Pharmaceuticals plc (13.29), less than Disc Medicine, Inc. (25.02), less than Larimar Therapeutics, Inc. (13.10), less than PepGen Inc. (7.45), less than Tyra Biosciences, Inc. (36.46), less than Pharvaris N.V. (18.45), less than Eliem Therapeutics, Inc. (0), less than Genenta Science S.p.A. (60.41), less than Opthea Limited (12.25), greater than Pardes Biosciences, Inc. (2.94), less than null (81.72),

Build a custom stock screener for Entrada Therapeutics, Inc. (TRDA) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Entrada Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Entrada Therapeutics, Inc. (TRDA) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Entrada Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.